BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Zymeworks Closes $3.5 Million Round of Financing and Announces Changes to its Board of Directors


6/22/2009 8:46:10 PM

VANCOUVER, British Columbia, Canada – Zymeworks Inc., a privately held computational biotechnology company, today announced the close of a financing totaling $3.5 million. The financing included an institutional investment by CTI Life Sciences Fund (“CTI”) and the completion of its existing private financing round. Further financial terms are not disclosed. Zymeworks will use the proceeds to fund ongoing validation and research programs leading to the advancement of Zymeworks’ protein therapeutics pipeline.

In conjunction with the financing, Dr. Shermaine Tilley of CTI and Mr. Kenneth Galbraith of Ventures West Management Inc. will be joining the Board of Directors. Dr. Andrew Wright and Mr. Amos Michelson will be stepping down as directors but will retain board observer status.

Dr. Tilley is a Principal at CTI and holds a Ph.D. in Biochemistry from the Johns Hopkins University School of Medicine and an MBA from the University of Toronto. She is also a member of the Toronto Society of Financial Analysts. Prior to joining CTI, Dr. Tilley was Senior Vice President at Drug Royalty Corporation where she managed the due diligence operations and participated in closing transactions totaling over $200M. She previously held faculty positions at the NYU School of Medicine and Public Health Research Institute, New York.

Mr. Galbraith is a General Partner at Ventures West and leads the firm’s biotechnology practice. He had served as Chairman and Interim CEO at AnorMED Inc. and Executive Vice President and Chief Financial Officer at QLT Inc. He holds a Bachelor of Commerce (Hon.) degree from the University of British Columbia and is a Chartered Accountant.

“We are delighted to have CTI on board and look forward to working with Dr. Tilley and the rest of the CTI team towards establishing Zymeworks as a leader in structure-guided protein therapeutics development. We view CTI’s investment alongside the continued financial support of our existing shareholders as a vote of confidence in Zymeworks’ technology and market opportunity,” says Dr. Ali Tehrani, President and CEO of Zymeworks. “We are also excited to have Mr. Ken Galbraith bring his considerable experience in the biotech sector to our board of directors. Furthermore, I would like to express my personal gratitude to Dr. Wright and Mr. Michelson for their years of guidance and support. Their ongoing involvement with the Company will ensure that Zymeworks will be best positioned for future growth and success.”

“We believe that Zymeworks is on the cusp of demonstrating substantial value in its protein engineering platform for the rapidly expanding ‘biobetters’ market, including the multi-billion dollar monoclonal antibodies market. We are enthusiastic to lead this investment round as well as to provide leadership in building the Company moving forward,” says Shermaine Tilley, Principal, CTI Life Sciences Fund.

About Zymeworks Inc.

Zymeworks is a computational biotechnology company researching and developing next-generation protein therapeutics. Zymeworks leverages proprietary insight into structure-function relationships generated by the ZymeCAD™ platform to optimize the efficacy and potency of protein therapeutics. Zymeworks is focused on developing a biotherapeutics pipeline through strategic collaborations and internal research programs. More information on Zymeworks can be found at http://www.zymeworks.com.

About CTI Life Sciences Fund

CTI is a Montreal-based limited partnership making venture capital investments in high quality emerging life sciences companies at the start-up and clinical development stage in North America, primarily in Canada. CTI has a diverse team of professionals in science and finance with extensive experience in the biotechnology and the pharmaceutical industries. The Fund works closely with entrepreneurs and researchers to increase the value of young companies. More information on CTI can be found at http://www.ctisciences.com.

Contact:

Zymeworks Inc.
Ali Tehrani, Ph.D.
President & CEO
info@zymeworks.com
Source: Zymeworks Inc.

CTI Life Sciences Fund
Shermaine Tilley, Ph.D., MBA
Principal
stilley@ctisciences.com



Read at BioSpace.com

Zymeworks
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES